Beijing Genomics Institute Touts Eventual Merck Deal
This article was originally published in PharmAsia News
Executive Summary
With Peter Kim, PhD, the president and EVP of Merck & Co. Inc.'s Merck Research Laboratories in attendance, in mid-September BGI (formerly the Beijing Genomics Institute) announced the signing of a statement of intent to form a working relationship with Merck. The organizations aim to utilize BGI's high-throughput DNA sequencing and analysis capabilities as the underpinning of a research collaboration, primarily to analyze genomic and epigenetic data generated using Merck samples
You may also be interested in...
Asia Spotlight: Merck Unveils $1.5 Billion Expansion In China With New Beijing R&D Center
While many Big Pharmas are cutting R&D budgets in response to patent cliffs, Merck is investing $1.5 billion in R&D in China, in what could be the largest ever pharma R&D investment in the country.
Merck Unveils $1.5 Billion Expansion In China With New Beijing R&D Center; Plans To Double R&D Team By 2014
While many Big Pharmas are cutting R&D budgets in response to patent cliffs, Merck is investing $1.5 billion in R&D in China, in what could be the largest ever pharma R&D investment in the country.
Merck And BGI Sign Global Deal Focused On Biomarkers, Genomics
After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies